Department of Defense (DoD) Health Program research opportunities are posted below. Grants with the shortest deadlines or that require pre-applications are posted first. Click here for archived DoD funding.

Contact the UAMS Research and Innovation for information on application tips, current UAMS DoD funding  grantees, and UAMS DoD reviewers. Contact the Office of Research and Sponsored Programs for submission assistance, eligibility questions, or other grant funding questions.

Department of Defense Peer Reviewed Alzheimer’s Research Program
DEADLINE: Pre-announcement currently
The DoD Peer Reviewed Alzheimer’s Research Program (PRARP) supports research on long-term consequences of traumatic brain injury for Alzheimer’s disease/dementias via 5 award mechanisms – Convergence Science Research Award, Innovation in Care and Support Award, Research Partnership Award (RPA), Accelerating Diagnostics for Traumatic Brain Injury Research Award (ADTBI) and Leveraging Approaches for Innovation in Care and Support Award (LEAP-InCASA).  Topical areas include: Paucity of Research Resources; Paucity of Clinical Studies; Diagnostics/Prognostics; Epidemiology; Quality of Life; and Family/Care Support. PRARP focus areas include: mechanisms of pathogenesis, biomarkers, epidemiology, novel target identification, and bioinformatics. Max funding of Level I – $225,000 (direct/indirect) costs for 3 yrs.  Level II – Max funding of $500,000 (direct/indirect costs) for 3 yrs. RPA – Max funding of $1.3 Million for 3 yrs.  ADTBI – Max funding of $2.8 million for 4 yrs. LEAP-InCASA – Max funding of $2.8 million for 4 yrs.



Dept. of Defense Amyotrophic Lateral Sclerosis Research Program
DEADLINE: Not yet announced
The FY20 ALSRP will support innovative/impactful research on new treatments for ALS.
Therapeutic Development Award – Pre-application required; full application submission is by invitation only; supports preclinical secondary validation and IND-enabling studies of ALS therapeutics and efficacy in one ALS-relevant model system with a lead molecule/class of compounds; and biomarker development. Max funding of $1,000,000 (direct/indirect) costs for 3 yrs.
Therapeutic Idea Award – Pre-application required; full application by invitation only; preclinical therapeutic development; preliminary data not required. Early Career Investigators encouraged to apply. Applications on biomarkers will qualify for more funding. Max funding of $500,000 (direct/indirect) costs or $600,000 (direct/indirect) costs for Therapeutic Relevant Biomarker option for 2 yrs.
Clinical Development Award – Pre-application required; full application submission by invitation only.
Supports leveraging of human-based ALS resources via clinical research; Early Career Investigators/Physician Scientists encouraged to apply.  Types of efforts supported include:
Using human subject-based resources to better define subtypes, predict therapeutic response, or assess prognosis; Correlating clinical trial-related biosamples, imaging, or epidemiological data with clinical outcomes; adding a secondary aim/goal to an anticipated/ongoing clinical trial, not otherwise supported by the trial; and studies to evaluate optimizing components of current ALS clinical care. Max funding of $300,000 (direct/indirect) costs for 2 yrs.
Department of Defense Neurofibromatosis Research Program (NFRP)
Neurofibromatosis Research Program (NFRP) to supports innovative, high-impact NF research.  Pre-application and application deadlines not yet announced. NFRP seeks to addresses: Biomarker discovery, utility, development, and validation; Non-tumor manifestations (Pain, Cognitive, Manifestations, Sleep, Heterogeneity of NF-related tumors; disease/treatment response markers using genetics, genomics, epigenetics, systems biology, metabolomics);Preclinical efficacy studies; Targets, drug discovery; Nutritional, environmental; and Health services research.

Clinical Trial Award – Funding must support a clinical trial and not used for preclinical studies; Scientific rationale/prelim data required for Phase I, II clinical trials. Max funding of $800,000 for (direct/indirect costs); Max funding $1M (direct/indirect costs) with  a collaborator is 4 yrs.
Exploration – Hypothesis Development Award – Prelim/published data encouraged, not required; Clinical trials allowed; Max $100,000 (direct/indirect costs) for 2 yrs.
Investigator-Initiated Research Award – Investigators must commit at least a 10% effort/budget period; Prelim/published data required; Clinical trials allowed; Max funding  $525,000 (direct/indirect costs); Max $575,000 (direct/indirect costs) with collaborator; Max funding $625,000 (direct/indirect costs) for 3 yrs.
New Investigator Award – NF experience is allowed, but not required; Prelim/or published data is required; Clinical trials not allowed; Max $450,000 (direct/indirect costs) for 3 yrs.
Early Investigator Research Award – Postdoctoral Ph.D. or M.D. PIs; Have at least 3 -6 yrs. of consecutive postdoctoral fellowship; Supports research opportunities focused on NF for individuals in the early stages of their careers; PIs must have a designated mentor who is an experienced NF researcher; Max $200,000 for (direct/indirect costs) for 2 yrs.
Synergistic Idea Award (NEW for FY20) – Supports partnerships between 2-3  investigators to address a NF problem (may be high risk with potential for high impact); Must show synergism (i.e., leveraging disciplines, expertise or critical resources) to advance the project such that the research outcomes as a whole will be realized rapidly/efficiently and could not otherwise be accomplished independently. Prelim/published data required; Synergy, Research Strategy, Personnel, and Impact most important review criteria; Clinical trials not allowed; Max $2M (direct/indirect costs) for 3 yrs.